Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Limited readies to reveal clinical data

Actinogen Limited readies to reveal clinical data

Actinogen Limited (ASX:ACW) has been granted a trading halt by the ASX pending the results of the CSF clinical data.

The company is focussed on the treatment of Alzheimer’s disease and mild cognitive impairment.

The halt will remain in place until the opening of trade on Wednesday 30th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile

Actinogen Medical Timeline

Newswire
December 30 2016

Related Articles

AZN2.jpg
January 10 2017
We look at what looks to be a savvy investment by the UK biotech.
Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
biotech_517925923_58abefa9e91cc.jpg
February 21 2017
“Our strategy of investing in future capacity will ensure our ability to provide quality service for this high level of customer need as our partners’ programmes progress,” said chief executive John Burt.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.